---
title: "Repligen Corporation (RGEN.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/RGEN.US.md"
symbol: "RGEN.US"
name: "Repligen Corporation"
industry: "Life Sciences Tools and Services"
---

# Repligen Corporation (RGEN.US)

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Location | US Market |
| Website | [www.repligen.com](https://www.repligen.com) |

## Company Profile

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:13.000Z

**Overall: B (0.40)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 7 / 62 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 11.74% |  |
| Net Profit YoY | 121.47% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 3.71 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 7.72B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 707.89M |  |


**Multi Score**: B

#### Profit Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 0.08% | D |
| Profit Margin | 0.25% | C |
| Gross Margin | 53.24% | B |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 11.74% | B |
| Net Profit YoY | 121.47% | A |
| Total Assets YoY | 3.29% | C |
| Net Assets YoY | 3.29% | C |

#### Cash Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 40730.15% | A |
| OCF YoY | 11.74% | B |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.25 | D |

#### Debt Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 28.75% | B |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Repligen Corporation",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "0.08%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "0.25%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "53.24%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "11.74%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "121.47%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "3.29%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "3.29%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "A",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "40730.15%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "11.74%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.25",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "B",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "28.75%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ChromaDex (US.CDXC) | A | A | A | B | B | A |
| 02 | Agilent Tech (US.A) | A | C | B | C | C | B |
| 03 | Waters (US.WAT) | A | B | B | C | C | B |
| 04 | WuXi Biologics (US.WXXWY) | B | B | D | A | B | B |
| 05 | West Pharmaceutical (US.WST) | B | B | B | B | C | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 4444.31 | 23/59 | 5388.11 | 5208.35 | 4732.24 |
| PB | 3.71 | 38/59 | 4.35 | 3.80 | 3.39 |
| PS (TTM) | 10.91 | 50/59 | 12.99 | 11.52 | 10.36 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-05T05:00:00.000Z

Total Analysts: **21**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 14 | 67% |
| Overweight | 3 | 14% |
| Hold | 4 | 19% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 137.72 |
| Highest Target | 220.00 |
| Lowest Target | 160.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/RGEN.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/RGEN.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/RGEN.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
